In the first quarter of the fiscal year employers cut 190,410 jobs, says a report from Challenger, Gray & Christmas.
The company's treatment, filgotinib, is being developed with Gilead Sciences.
The pharmaceutical company also reported a net loss lower than analysts' expectations.
Conn's fourth-quarter revenue missed analysts' estimates. The stock is regaining losses.
The social media site proposed a max offering price of $100 million for its shares.
Poor weather and customers taking days off at the holidays hurt Cintas' sales during its fiscal Q3.
Greenbrier tumbles after its outlook for the fiscal second quarter widely misses expectations.
Company executives anticipate a poor first quarter in the new fiscal year.
The Iowa-based company declared a dividend of 29 cents for the third quarter.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.